Analysts Offer Insights on Healthcare Companies: Seattle Genetics (SGEN) and Stemline Therapeutics Inc (STML)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seattle Genetics (SGEN) and Stemline Therapeutics Inc (STML) with bullish sentiments.

Seattle Genetics (SGEN)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Seattle Genetics, with a price target of $98. The company’s shares closed yesterday at $71.09.

Fein noted:

“We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($63.1 HL + $3.6 relapsed sALCL+ $11.2 frontline PTCL + $17.6 platform + $2.6 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. April 26, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2Seattle Genetics, Inc.”

According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.2% and a 44.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $81.25.

See today’s analyst top recommended stocks >>

Stemline Therapeutics Inc (STML)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc today and set a price target of $35. The company’s shares closed yesterday at $14.25.

Selvaraju commented:

“As we roll forward the DCF analysis, the estimated market value of the firm has increased to $1.5B from $1.46B, which includes the asset value for 15% discount rate and 2% terminal growth rate. The company has approximately 43.6M shares outstanding. Probabilities of success ascribed to SL-401 and SL-701 are 100% and 45%, respectively.”

According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.2% and a 32.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $29.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts